Tumaini Trial Launch: WHO begins Ebola vaccine study in DRC; aims to protect against Bundibugyo strain
Reported by Times of India World, not nibnow. We are not the publisher of this story, only the source is.
The trial could determine whether the Ervebo vaccine can protect people from the Bundibugyo strain of Ebola that has caused thousands of cases and deaths in the DRC, potentially shaping the response to the current outbreak.
In a historic move, the World Health Organization has launched its inaugural clinical trial for an Ebola vaccine in the Democratic Republic of Congo. This trial aims to assess the efficacy of the Ervebo vaccine against the Bundibugyo virus amid a severe outbreak that has resulted in over 9,700 cases and 4,600 fatalities since May.
The World Health Organization coordinates global health research and launches vaccine trials, while Ebola is a viral disease that can cause severe outbreaks; the Bundibugyo strain is one of several Ebola variants that have prompted vaccine development.
- •Release of interim or final efficacy data from the trial
- •Decisions by health authorities on broader use of Ervebo if it proves effective
- •Trends in new Ebola cases and deaths in the DRC as the outbreak evolves